NaPro Reports Fourth Quarter and Full-Year 2003 Results BOULDER,
Colo., March 11 /PRNewswire-FirstCall/ -- NaPro BioTherapeutics,
Inc. today announced the results of operations for the fourth
quarter and year ended December 31, 2003. The net income for the
fourth quarter of 2003 was $49.1 million, or $1.59 basic income per
share, and $1.56 diluted income per share, including a one-time
gain from the sale of the generic injectable paclitaxel business of
$54.6 million. This compares to a net lossof $1.1 million, or $0.04
basic and diluted loss per share for the fourth quarter of 2002.
After tax income from discontinued operations was $55.5 million in
the fourth quarter of 2003, compared with $3.9 million in income
from discontinued operationsin the fourth quarter of 2002. For the
year ended December 31, 2003, NaPro reported net income of $38.1
million, or $1.24 basic income per share, and $1.23 diluted income
per share, including a one-time gain of $54.6 million from the sale
of its generic injectable paclitaxel business. This compares to a
net loss of $8.7 million for year ended December 31, 2002, or $0.29
basic and diluted loss per share. NaPro recognized after tax income
from its discontinued operations of $60.0 million in 2003, compared
to income of $11.5 million in 2002. As of December 31, 2003, NaPro
had $50.8 million in cash, cash equivalents and marketable
securities. "Calendar year 2003 was a pivotal year for NaPro
BioTherapeutics," stated Leonard P. Shaykin, NaPro's Chairman and
Chief Executive Officer. "With the sale of our paclitaxel business
we changed the fundamental direction of the company. With the
proceeds from this important sale we have begun to fund the
pre-clinical development of our new proprietary therapeutic
programs in both cancer and hereditary disease. We look forward,
subject to regulatory clearance, to advancing two of these
therapeutic candidates into human clinical trials this calendar
year," continued Mr. Shaykin. 2003 Highlights Focus on Proprietary
Therapeutics Development -- Two Sales Reposition NaPro Sale of the
Worldwide Paclitaxel Business. In December 2003, NaPro completed
the sale of its worldwide generic injectable paclitaxel business to
Mayne Pharma (USA) Inc., a subsidiary of Mayne Group Ltd., for
$71.7 million in cash minus an inventory adjustment of $4.6
million. From the proceeds of the sale, NaPro retired $21.9 million
in debt (including accrued interest)and payables arising from its
development relationship with Abbott Laboratories and entered
calendar year 2004 with over $50 million dollars in cash and cash
equivalents. Sale of Technical and Analytical Services Group. In
April 2003, NaPro sold its technical and analytical services group
to privately held ChromaDex, Inc., a leading supplier of
phytochemical reference standards to the nutraceutical, dietary
supplement, and functional food industries. NaPro transferred
employees, specific physical assets, and real estate leases to the
company, and in return, acquired an approximate 15% equity stake in
ChromaDex, Inc. With the sales mentioned above, NaPro is
re-positioned to support the ongoing development of its new
proprietary therapeutic products in the areas of oncology and
hereditary disease. NaPro currently has four pre-clinical oncology
candidates, two of which are anticipated to enter human clinical
trials this year. The Company also has two hereditary disease
programs in pre-clinical development, one for the treatment of
Huntington's Disease and the other for the treatment of Sickle Cell
Disease. -- Mylan Litigation On October 6, 2003, the Federal
District Court in the Western District of Pennsylvania made a
number of rulings in favor of the Company in its patent
infringement lawsuit against Mylan Laboratories, Inc. ("Mylan")
regarding certainpaclitaxel formulation patents. The District Court
ruled that Mylan infringes NaPro patents related to both stabilized
formulations of paclitaxel and as well as methods for making stable
formulations. The court also ruled that the inventors listed on the
NaPro patents were the first to invent the compositions and methods
claimed in such patents. The District Court also adopted NaPro's
interpretations of the patent claims asserted against Mylan in this
case. On December 23, 2003, the District Court ruled again in
NaPro's favor that NaPro's patents were valid and that Mylan's
claims that the patents were procured through inequitable conduct
and fraud on the patent office were neither true nor justified. In
February 2004, the Federal Circuit appellate court stayed the
District Court's injunction order, which would have prevented Mylan
from selling the infringing products, pending a ruling on Mylan's
appealto the Federal Circuit. A trial to resolve any issues which
may be remanded to the District Court as a result of Mylan's
appeal, as well as determining any damages owed by Mylan in this
case, has been set for February 2005. The patents, which are the
subject of this litigation, were part of the sale of the paclitaxel
business to Mayne Pharma. The terms of the sale provide that NaPro
will be entitled to a portion of any cash award received with
respect to the final adjudication or settlement of this litigation.
Mayne Pharma, however, is in full control of the litigation, is
responsible for the full cost of prosecuting it, and may direct it,
or settle it, upon any terms it chooses. About NaPro
BioTherapeutics NaPro BioTherapeutics, Inc. is a life science
company focused on the development of therapies for the treatment
of cancer and hereditary disease. For more information about NaPro
and its technologies, visit NaPro's web site at
http://www.naprobio.com/ . Forward Looking Statement The statements
in this press release and on the Company's web site that are not
historical facts are forward-looking statements that represent
management's beliefs and assumptions as of the date of this
presentation, based on currently available information.
Forward-looking statements can be identified by the use of words
such as "believes," "intends," "estimates," "may," "will,"
"should," "anticipates," "expected" or comparable terminology orby
discussions of strategy. Although the Company believes that the
expectations reflected in such forward-looking statements are
reasonable, it cannot assure that these expectations will prove to
be correct. Such statements involve risks and uncertainties
including those factors identified under the captions "Risk
Factors," "Special Note Regarding Forward Looking Statements" or
"Cautionary Note Regarding Forward Looking Statements" in the
Company's documents filed from time to time with the SEC, including
the Company's Current Report on Form 8-K/A, dated February 11,
2004. Should one or more of these risks materialize (or the
consequences of such a development worsen), or should the
underlying assumptions prove incorrect, actual results could differ
materially from those forecasted or expected. The Company disclaims
any intention or obligation to update publicly or revise such
statements whether as a result of new information, future events or
otherwise. For further information, please contact L. Robert Cohen,
Vice President, Investor Relations of NaPro BioTherapeutics, Inc.,
+1-212-218-8715. NaPro BioTherapeutics, Inc. Balance Sheets (In
thousands) December 31, December 31, 2003 2002 (Unaudited)
(Unaudited) ASSETS Current assets: Cash and cash equivalents
$40,785 $6,762 Short-term investments 9,997 -- Accounts receivable
1,495 -- Prepaid expense and other current assets 596 1,003 Assets
held for sale 205 33,463 Total current assets 53,078 41,228
Property, plant and equipment, net 1,156 2,042 Other assets 3,532
2,058 Total assets $57,766 $45,328 LIABILITIES AND STOCKHOLDERS'
EQUITY Total current liabilities $6,025 $7,633 Notes payable - long
term 41 19,861 Deferred income - long term -- 5,887 Convertible
debentures 5,702 5,151 Total stockholders' equity 45,998 6,796
Total liabilities and stockholders' equity $57,766 $45,328 NaPro
BioTherapeutics, Inc. Statements of Operations (In thousands,
except per sharedata) (Unaudited) Three Months Ended Year Ended
December 31, December 31, 2003 2002 2003 2002 (Unaudited)
(Unaudited) (Unaudited) (Unaudited) Operating Expenses: Research
and development $3,071 $2,456 $9,890 $10,192 General and
administrative 3,133 2,443 11,256 9,519 Operating loss 6,204 4,899
21,146 19,711 Other income (expense): Interest income 46 42 110 267
Interest expense (223) (205) (878) (723) Net loss from continuing
operations (6,381) (5,062) (21,914) (20,167) Discontinued
Operations: Income from discontinued operations (including gain on
sale of $54,553 in 2003) 56,096 3,949 60,686 11,502 Provision for
federal income tax (644) -- (644) -- Net income (loss) $49,071
$(1,113) $38,128 $(8,665) Basic and diluted loss per share from
continuing operations $(0.21) $(0.17) $(0.71) $(0.68) Basic income
(loss) per share from discontinued operations $1.80 $0.13 $1.95
$0.39 Diluted income (loss) per share from discontinued operations
$1.76 $0.13 $1.94 $0.37 Basic income (loss) per share $1.59 $(0.04)
$1.24 $(0.29) Diluted income (loss) per share $1.56 $(0.04) $1.23
$(0.29) Basic weighted average shares outstanding 30,842 29,826
30,801 29,606 Diluted weighted average shares outstanding relating
to discontinued operations 31,483 29,943 30,955 31,268 Diluted
weighted average shares outstanding 31,483 29,826 30,955 29,606
DATASOURCE: NaPro BioTherapeutics, Inc. CONTACT: L. Robert Cohen,
Vice President, Investor Relations, of NaPro BioTherapeutics, Inc.,
+1-212-218-8715; or Investors, Lilian Stern of Stern Investor
Relations, Inc., +1-212-362-1200; or Media, Peter Steinerman,
+1-516-374-3031, both for NaPro BioTherapeutics, Inc. Web site:
http://www.naprobio.com/
Copyright
Napro Biotherapeutics (NASDAQ:NPRO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Napro Biotherapeutics (NASDAQ:NPRO)
Historical Stock Chart
From Jul 2023 to Jul 2024